Quantitative background parenchymal enhancement and fibro-glandular density at breast MRI: Association with BRCA status.


Journal

European radiology
ISSN: 1432-1084
Titre abrégé: Eur Radiol
Pays: Germany
ID NLM: 9114774

Informations de publication

Date de publication:
Sep 2023
Historique:
received: 01 08 2022
accepted: 22 02 2023
revised: 20 02 2023
medline: 11 8 2023
pubmed: 6 4 2023
entrez: 5 4 2023
Statut: ppublish

Résumé

To investigate whether MRI-based measurements of fibro-glandular tissue volume, breast density (MRBD), and background parenchymal enhancement (BPE) could be used to stratify two cohorts of healthy women: BRCA carriers and women at population risk of breast cancer. Pre-menopausal women aged 40-50 years old were scanned at 3 T, employing a standard breast protocol including a DCE-MRI (35 and 30 participants in high- and low-risk groups, respectively). The dynamic range of the DCE protocol was characterised and both breasts were masked and segmented with minimal user input to produce measurements of fibro-glandular tissue volume, MRBD, and voxelwise BPE. Statistical tests were performed to determine inter- and intra-user repeatability, evaluate the symmetry between metrics derived from left and right breasts, and investigate MRBD and BPE differences between the high- and low-risk cohorts. Intra- and inter-user reproducibility in estimates of fibro-glandular tissue volume, MRBD, and median BPE estimations were good, with coefficients of variation < 15%. Coefficients of variation between left and right breasts were also low (< 25%). There were no significant correlations between fibro-glandular tissue volume, MRBD, and BPE for either risk group. However, the high-risk group had higher BPE kurtosis, although linear regression analysis did not reveal significant associations between BPE kurtosis and breast cancer risk. This study found no significant differences or correlations in fibro-glandular tissue volume, MRBD, or BPE metrics between the two groups of women with different levels of breast cancer risk. However, the results support further investigation into the heterogeneity of parenchymal enhancement. • A semi-automated method enabled quantitative measurements of fibro-glandular tissue volume, breast density, and background parenchymal enhancement with minimal user intervention. • Background parenchymal enhancement was quantified over the entire parenchyma, segmented in pre-contrast images, thus avoiding region selection. • No significant differences and correlations in fibro-glandular tissue volume, breast density, and breast background parenchymal enhancement were found between two cohorts of women at high and low levels of breast cancer risk.

Identifiants

pubmed: 37017702
doi: 10.1007/s00330-023-09592-2
pii: 10.1007/s00330-023-09592-2
pmc: PMC10415521
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

6204-6212

Commentaires et corrections

Type : ErratumIn

Informations de copyright

© 2023. The Author(s).

Références

Breast Cancer Res. 2011;13(6):223
pubmed: 22114898
Med Phys. 2011 Jan;38(1):5-14
pubmed: 21361169
BMC Med Imaging. 2021 Feb 19;21(1):32
pubmed: 33607959
Radiology. 2011 Jul;260(1):50-60
pubmed: 21493794
Acad Radiol. 2014 Nov;21(11):1394-401
pubmed: 25179563
Br J Radiol. 2020 Feb 01;93(1106):20190639
pubmed: 31674798
Radiology. 2019 Sep;292(3):562-563
pubmed: 31237810
IEEE Trans Med Imaging. 2010 Jun;29(6):1310-20
pubmed: 20378467
Radiographics. 2018 Jul-Aug;38(4):983-996
pubmed: 29856684
Breast Cancer (Dove Med Press). 2019 Apr 10;11:151-164
pubmed: 31040712
J Clin Med. 2019 May 24;8(5):
pubmed: 31137728
J Natl Cancer Inst. 2010 Aug 18;102(16):1224-37
pubmed: 20616353
Radiology. 2019 Sep;292(3):552-561
pubmed: 31237494
PLoS One. 2016 Mar 24;11(3):e0152152
pubmed: 27011312
J Magn Reson Imaging. 2020 Jan;51(1):43-61
pubmed: 31004391
Radiology. 2008 Feb;246(2):348-53
pubmed: 18227535
Clin Imaging. 2022 Mar;83:41-50
pubmed: 34953310
Breast Cancer Res Treat. 2014 Apr;144(3):479-502
pubmed: 24615497
Radiology. 2015 Aug;276(2):371-80
pubmed: 25965809
Breast Cancer Res. 2016 Oct 12;18(1):102
pubmed: 27729066

Auteurs

Rosie Goodburn (R)

CRUK Cancer Imaging Centre, The Institute of Cancer Research and Royal Marsden Foundation Trust, London, UK. rosie.goodburn@icr.ac.uk.
The Royal Marsden NHS Foundation Trust, Sutton, UK. rosie.goodburn@icr.ac.uk.

Evanthia Kousi (E)

CRUK Cancer Imaging Centre, The Institute of Cancer Research and Royal Marsden Foundation Trust, London, UK.
The Royal Marsden NHS Foundation Trust, Sutton, UK.

Clarrissa Sanders (C)

St Georges University Hospitals NHS Foundation Trust, London, UK.

Alison Macdonald (A)

The Royal Marsden NHS Foundation Trust, Sutton, UK.

Erica Scurr (E)

The Royal Marsden NHS Foundation Trust, Sutton, UK.

Catey Bunce (C)

The Royal Marsden NHS Foundation Trust, Sutton, UK.

Komel Khabra (K)

The Royal Marsden NHS Foundation Trust, Sutton, UK.

Mamatha Reddy (M)

St Georges University Hospitals NHS Foundation Trust, London, UK.

Louise Wilkinson (L)

The Royal Marsden NHS Foundation Trust, Sutton, UK.

Elizabeth O'Flynn (E)

The Royal Marsden NHS Foundation Trust, Sutton, UK.

Steven Allen (S)

The Royal Marsden NHS Foundation Trust, Sutton, UK.

Maria Angélica Schmidt (MA)

CRUK Cancer Imaging Centre, The Institute of Cancer Research and Royal Marsden Foundation Trust, London, UK.
The Royal Marsden NHS Foundation Trust, Sutton, UK.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH